Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274100 · ClinicalTrials.gov registry record · Phase 1
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 394
- Enrollment target
NCT05274100 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 394 participants.
The verdict
NCT05274100, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 394 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess the relative bioavailability of risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy 1) and to assess the relative bioavailability of risankizumab in the to-be-marketed Dose A liquid vial versus the Dose B liquid vial used in the Phase 3 studies (Substudy 2).
Interventions
- DRUG Risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2021-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05274100
The ClinicalTrials.gov registry entry for NCT05274100 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risankizumab is the first listed.
NCT05274100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05274100 about?
NCT05274100 is a clinical study titled "Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants". The primary objectives of this study are to assess the relative bioavailability of risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy 1) and to assess the relative bioavailability of risankizumab in the to-be-marketed Dose A liquid vial versus the Dose B liqu...
What is the current status of trial NCT05274100?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 394 participants. The study started on 2020-09-01. Estimated completion is 2021-07-06.
What interventions are being tested in trial NCT05274100?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT05274100?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.